Shubham Pant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (24)
Background Somatic FGFR gene alterations ( FGFRalt ) may act as oncogenic drivers across several cancers. The prognostic impact of FGFRalt in solid tumors is not fully understood. We assessed the prognostic impact of FGFRalt on overall survival (OS) in a tumor‐agnostic real‐world cohort of patients with advanced solid tumors. Methods This was a retrospective, observational, comparative cohort analysis that used data from a nationwide de‐identified clinico‐genomic database. Patients were included if they had advanced/metastatic disease, were aged ≥ 18 years at the time of diagnosis, had evidence of genomic testing for FGFRalt , and had initiated first‐line systemic therapy for their cancer. Patients without FGFR alterations ( FGFRneg ) were matched 3:1 with patients with FGFRalt using a combination of exact matching on tumor type and Mahalanobis‐distance matching on selected clinical confounders. The primary endpoint was OS from time of initiation of first‐line therapy in patients with FGFRalt versus FGFRneg . To further mitigate bias, delayed entry models and covariate‐adjusted stratified Cox models were implemented. Results The final cohort included 1012 patients (253 FGFRalt , 759 FGFRneg ), across 30 tumor types. There were no significant differences in real‐world OS from first‐line therapy between FGFRalt and FGFRneg groups (hazard ratio 0.97; p = 0.78). Median OS from initiation of first‐line therapy was 1.13 years (95% confidence interval [CI] 0.92–1.52) and 1.01 years (0.89–1.15) for the FGFRalt and FGFRneg groups, respectively. Conclusions In this matched‐cohort real‐world analysis, presence of FGFRalt had no impact on the prognosis of patients with advanced solid tumors receiving standard‐of‐care treatment.
Year:
2025
We sought to assess discordance of HER2 status in patients with HER2-amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with metastatic solid tumors and HER2 expression by IHC or amplification by FISH/next-generation sequencing on local testing underwent central HER2 IHC/FISH testing with either archival or fresh biopsies and were evaluated for discordance in HER2 status. 70 patients (12 cancer types) underwent central HER2 reevaluation, including 57 (81.4%) with a new biopsy. In 30 patients with HER2 3+ on local IHC, 21 (70.0%) were 3+, 5 (16.7%) were 2+, 2 (6.7%) were 1+, and 2 (6.7%) had 0 HER2 expression on central IHC. In 15 patients whose cancers were 2+ on local IHC, 2 (13.3%) were 3+, 5 (33.3%) were 2+, 7 (46.7%) were 1+, and 1 (6.7%) had 0 HER2 expression on central IHC. HER2 discordance was seen in 16 of 52 (30.8%) of patients with HER2 overexpression/amplification who underwent a new image-guided biopsy. Discordance was observed in 10 (33.3%) of 30 patients who received intervening HER2-targeted therapy and in 6 (23.8%) of 22 patients who did not. In the 8 patients who had central HER2 assessment from the same archival block used for local testing, none were discordant. Discordance of HER2 status is common in patients with tumors previously identified as HER2-expressing, especially in patients with HER2 2+ tumors. Repeat biomarker evaluation may have value when considering HER2-targeted therapies.
Year:
2025
Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.
Year:
2024
Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRAS G12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRAS G12D mutated patient-derived organoids.
Year:
2024
Supplemental Figure 1: Acquired resistance to KRAS G12C inhibition in PDAC and other GI cancers. Supplemental Figure 2: MRTX1133 sensitivity across KRAS G12D mutant in vitro models of PDAC. Supplemental Figure 3: Isogenic models of acquired resistance to MRTX1133. Supplemental Figure 4: In vivo treatment and tumor monitoring for the KPC PDAC mouse model. Supplemental Figure 5: Genomic characterization of KPC tumors. Supplemental Figure 6: snRNA-seq quality metrics and description of the tumor microenvironment. Supplemental Figure 7: Identification and characterization of malignant cell populations. Supplemental Figure 8: Characterization of malignant metaprograms in KPC tumors. Supplemental Figure 9: Treatment with MRTX1133 induces modest changes in the immune microenvironment following tumor regression. Supplemental Figure 10: Treatment of 6694C2-LM tumors with MRTX1133 reduces granulocytes but has little effect on T cells. Supplemental Figure 11: Neoadjuvant and adjuvant therapy in a metastatic model of PDAC.
Year:
2024
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRAS G12C -mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS , and amplifications of KRAS G12C , MYC , MET , EGFR , and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRAS G12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the Kras LSL-G12D/+ ; Trp53 LSL-R172H/+ ; p48- Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras , Yap1 , Myc , Cdk6, and Abcb1a/b , and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRAS G12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018
Year:
2024
Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRAS G12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRAS G12D cell lines.
Year:
2024
We sought to assess discordance of HER2 status in patients with HER2 amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with metastatic solid tumors and HER2 expression by immunohistochemistry (IHC) or amplification by fluorescent in situ hybridization (FISH)/next generation sequencing (NGS) on local testing underwent central HER2 IHC/FISH testing with either archival or fresh biopsies and were evaluated for discordance in HER2 status. 70 patients (12 cancer types) underwent central HER2 reevaluation, including 57 (81.4%) with a new biopsy. In 30 patients with HER2 3+ on local IHC, 21 (70.0%) were 3+, 5 (16.7%) were 2+, 2 (6.7%) were 1+, and 2 (6.7%) had 0 HER2 expression on central IHC. In 15 patients whose cancers were 2+ on local IHC, 2 (13.3%) were 3+, 5 (33.3%) were 2+, 7 (46.7%) were 1+, and 1 (6.7%) had 0 HER2 expression on central IHC. HER2 discordance was seen in 16 of 52 (30.8%) of patients with HER2 overexpression/amplification who underwent a new image-guided biopsy. Discordance was observed in 10 (33.3%) of 30 patients who received intervening HER2-targeted therapy and in 6 (23.8%) of 22 patients who did not. In the 8 patients who had central HER2 assessment from the same archival block used for local testing, none were discordant. Discordance of HER2 status is common in patients with tumors previously identified as HER2-expressing, especially in patients with HER2 2+ tumors. Repeat biomarker evaluation may have value when considering HER2-targeted therapies.
Year:
2024
Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.
Year:
2024
Supplementary Figure 1: HER2 status of patients and corresponding PDX models. HER2 expression was assessed by IHC and ERBB2 amplification status by FISH and NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations in available CLIA genomic testing on archival patient samples (matching PDX hosts). CLIA results were not available for patients matching PDX.003.025, PDX.003.263, and PDX.003.230. Supplementary Figure 2: Actionable gene alterations in patient biopsies compared to the alteration in the resulting PDX as determined by whole exome sequencing on both. Supplementary Figure 3: Cell viability assay with crizotinib. Cells were treated with crizotinib at serial dilutions for 72 hours. Following SRB staining, IC50 was calculated using CalcuSyn. Supplementary Figure 4. In vivo assessment of zanidatamab in combination with BET inhibitor JQ1. 50 mg/kg JQ1 had no antitumor effects as single agent and did not add benefit when combined with 16 mg/kg zanidatamab.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (42)
Janos Roszik
The University of Texas MD Anderson Cancer Center
Alexander Jordan
Assistant Professor
Yale University
Stephanie Dougan
Associate Professor
Dana-Farber Cancer Institute
Christina Lynn Roland
The University of Texas MD Anderson Cancer Center
Neeta Somaiah
Professor and Chair
The University of Texas MD Anderson Cancer Center
Eliezer Van Allen
Professor
Harvard University
Ben Stanger
University of Pennsylvania
Richard Gorlick
The University of Texas MD Anderson Cancer Center
Aung Naing
The University of Texas MD Anderson Cancer Center
Peter Winter
Principal Investigator
Broad Institute
Vivek Subbiah
Professor of Medicine and of Pediatrics
Stanford University
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Shreyaskumar Patel
Professor
The University of Texas MD Anderson Cancer Center
Anil Korkut
The University of Texas MD Anderson Cancer Center
Paula Pohlmann
The University of Texas MD Anderson Cancer Center
Douglas J. Harrison
-
Justin Moyers
-
Anthony P. Conley
Associate Professor
The University of Texas MD Anderson Cancer Center
Vanessa Jensen
Chair
The University of Texas MD Anderson Cancer Center
Sarina Piha-Paul
Professor
The University of Texas MD Anderson Cancer Center
Paola A. Guerrero
Research Group Leader
The University of Texas MD Anderson Cancer Center
Siqing Fu
Professor
The University of Texas MD Anderson Cancer Center
Srivatsan Raghavan
Assistant Professor
Dana-Farber Cancer Institute
David S. Hong
The University of Texas MD Anderson Cancer Center
Milind Javle
PROFESSOR
The University of Texas MD Anderson Cancer Center
J Andrew Livingston
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
VINOD RAVI
Associate Professor
The University of Texas MD Anderson Cancer Center
Valerae Lewis
Professor and Chair
MD Anderson Cancer Center
Ying Yuan
Professor
The University of Texas MD Anderson Cancer Center
Simona Cristea
Dana-Farber Cancer Institute
Anirban Maitra
Laura and Isaac Perlmutter Professor of Pathology
NYU Langone Health
Michael P. Kim
Associate Professor
The University of Texas MD Anderson Cancer Center
Cynthia Herzog
Professor
MD Anderson Cancer Center
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Wei-Lien Wang
Associate Professor
The University of Texas MD Anderson Cancer Center
Timothy Yap
The University of Texas MD Anderson Cancer Center
Ravin Ratan
Assistant Professor
The University of Texas MD Anderson Cancer Center
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Jaffer A. Ajani
Professor
The University of Texas MD Anderson Cancer Center
Alex K. Shalek
J. W. Kieckhefer Professor
Massachusetts Institute of Technology
Jennifer Roth
Broad Institute
Make your next move.
Prepare your application
Review drafts before you send them.